Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1535-1537

  Dutta, Noton K ^a   Alsultan, Abdullah ^b   Peloquin, Charles A ^b   Karakousis, Petros C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 DEACETYLRIFAPENTINE; DEACETYLRIFAMPICIN; DRUG METABOLITE; RIFAMPICIN; RIFAPENTINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GUINEA PIG; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STEADY STATE;

ANIMALS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUINEA PIGS; HOST SPECIFICITY; HUMANS; MICE; RIFAMPIN;

EID: 84874035752     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01933-12     Document Type: Article

References (11)

1. Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC. 2012. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob. Agents Chemother. 56:3726 -3731.
2. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob. Agents Chemother. 56:4331-4340.
3. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW. 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: Study 29 of the Tuberculosis Trials Consortium. J. Infect. Dis. 206:1030 -1040.
4. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. 2007. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51:2546 -2551.
5. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. 2012. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin. Pharmacol. Ther. 91: 881-888.
6. Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K, Goldberg S. 2004. Pharmacokinetics of rifapentine at 600, 900, and 1, 200 mg during once-weekly tuberculosis therapy. Am. J. Respir. Crit. Care Med. 169:1191-1197.
7. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH, Karakousis PC. 2010. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J. Antimicrob. Chemother. 65:729 -734.
8. Dooley K, Flexner C, Hackman J, Peloquin CA, Nuermberger E, Chaisson RE, Dorman SE. 2008. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob. Agents Chemother. 52:4037- 4042.
9. Peloquin CA, Namdar R, Singleton MD, Nix DE. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
10. Reith K, Keung A, Toren PC, Cheng L, Eller MG, Weir SJ. 1998. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab. Dispos. 26:732-738.
11. Rastogi N, Goh KS, Berchel M, Bryskier A. 2000. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J. Antimicrob. Chemother. 46:565-570.